StreetInsider.com News Articles

Form 8-K Protagenic Therapeutics, For: Feb 03

Tue, 03 Mar 2026 06:05:00 +0000

si-local-file:///var/storage/secattach/20260303/26095905.html

Form 8-K Protagenic Therapeutics, For: Feb 03

Tue, 03 Mar 2026 06:05:00 +0000

si-local-file:///var/storage/secattach/20260303/26095905.html

Form 8-K Protagenic Therapeutics, For: Feb 17

Tue, 24 Feb 2026 06:04:00 +0000

si-local-file:///var/storage/secattach/20260224/26046160.html

Form 8-K Protagenic Therapeutics, For: Feb 17

Tue, 24 Feb 2026 06:04:00 +0000

si-local-file:///var/storage/secattach/20260224/26046160.html

Form NT 10-Q Protagenic Therapeutics, For: Dec 31

Wed, 18 Feb 2026 06:49:00 +0000

si-local-file:///var/storage/secattach/20260218/26017505.html

Form NT 10-Q Protagenic Therapeutics, For: Dec 31

Wed, 18 Feb 2026 06:49:00 +0000

si-local-file:///var/storage/secattach/20260218/26017505.html

Form 25-NSE Protagenic Therapeutics, Filed by: Nasdaq Stock Market LLC

Fri, 23 Jan 2026 16:43:00 +0000

si-local-file:///var/storage/secattach/20260123/25887880.html

Form 25-NSE Protagenic Therapeutics, Filed by: Nasdaq Stock Market LLC

Fri, 23 Jan 2026 16:43:00 +0000

si-local-file:///var/storage/secattach/20260123/25887880.html

Form 8-K Protagenic Therapeutics, For: Dec 31

Mon, 05 Jan 2026 07:45:00 +0000

si-local-file:///var/storage/secattach/20260105/25801380.html

Form 8-K Protagenic Therapeutics, For: Dec 31

Mon, 05 Jan 2026 07:45:00 +0000

si-local-file:///var/storage/secattach/20260105/25801380.html

Protagenic reports positive safety results from PT00114 phase 1 study

Tue, 09 Dec 2025 08:46:14 +0000

Protagenic Therapeutics Inc. (NASDAQ: PTIX) reported positive safety results from its Phase 1 multiple-dose study of PT00114, a synthetic analogue of a naturally occurring brain peptide designed to address stress-related neuropsychiatric conditions.

The study evaluated safety, tolerability, and pharmacokinetic profiles of PT00114 in healthy volunteers across multiple dose levels. All planned cohorts completed dosing, according to the company's statement.

The preliminary analysis showed PT00114 was well tolerated across all dose ranges studied. Reported adverse events were consistent with expectations for a peptide-based injectable therapy, including injection-site reactions. No serious adverse events occurred and all participants completed their assigned dosing schedules.

"These results provide

Results from Phase 1 Multiple-Dose Study of PT00114

Tue, 09 Dec 2025 08:46:00 +0000

Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions

NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing therapeutics that target the biology of chronic stress and its downstream psychiatric and neurologic effects, today reported positive topline safety results from its Phase 1 Multiple Dose (MD) study of PT00114.

PT00114 is a synthetic analogue of a naturally occurring brain peptide thought to be involved in restoring homeostasis following prolonged exposure to stress. Its mechanism of

Results from Phase 1 Multiple-Dose Study of PT00114

Tue, 09 Dec 2025 08:46:00 +0000

Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions

PT00114 is a synthetic analogue of a naturally occurring brain peptide thought to be involved in restoring homeostasis following prolonged exposure to stress. Its mechanism of

Form DEF 14A Protagenic Therapeutics, For: Dec 05

Fri, 05 Dec 2025 16:53:00 +0000

si-local-file:///var/storage/secattach/20251205/25706912.html

Form DEF 14A Protagenic Therapeutics, For: Dec 05

Fri, 05 Dec 2025 16:53:00 +0000

si-local-file:///var/storage/secattach/20251205/25706912.html

Protagenic Therapeutics receives NASDAQ delisting notice

Fri, 28 Nov 2025 05:57:34 +0000

Protagenic Therapeutics, Inc. (NASDAQ: PTIX) received a notification from Nasdaq indicating the company violated two listing requirements, according to a press release statement.

The Nasdaq Listing Qualifications Staff determined the company no longer meets the minimum $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1), based on equity reported in the company's transition report for the period ended June 30, 2025. The company also violated Listing Rule 5250(c)(1) for delayed filing of its Form 10-Q for the quarter ended September 30, 2025.

Under Nasdaq Listing Rule 5815, the exchange issued a determination to delist the company's securities because Protagenic recently regained compliance

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

Thu, 27 Nov 2025 03:45:00 +0000

NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications Staff (the "Staff") indicating that the Company is not in compliance with Nasdaq Listing Rules 5550(b)(1) (minimum stockholders' equity) and 5250(c)(1) (timely filing of periodic reports).

The Staff determined that, based on the stockholders' equity reported in the Company's Transition Report on Form 10-QT for the period ended June 30, 2025, the Company no longer satisfies the minimum $2.5 million stockholders' equity

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

Thu, 27 Nov 2025 03:45:00 +0000

Form 10-Q Protagenic Therapeutics, For: Sep 30

Wed, 26 Nov 2025 17:27:00 +0000

si-local-file:///var/storage/secattach/20251126/25672016.html

Form 10-Q Protagenic Therapeutics, For: Sep 30

Wed, 26 Nov 2025 17:27:00 +0000

si-local-file:///var/storage/secattach/20251126/25672016.html

Form 8-K Protagenic Therapeutics, For: Nov 20

Wed, 26 Nov 2025 16:19:00 +0000

si-local-file:///var/storage/secattach/20251126/25671141.html

Form 8-K Protagenic Therapeutics, For: Nov 20

Wed, 26 Nov 2025 16:19:00 +0000

si-local-file:///var/storage/secattach/20251126/25671141.html

Form NT 10-Q Protagenic Therapeutics, For: Sep 30

Fri, 14 Nov 2025 17:05:00 +0000

si-local-file:///var/storage/secattach/20251114/25619141.html

Form NT 10-Q Protagenic Therapeutics, For: Sep 30

Fri, 14 Nov 2025 17:05:00 +0000

si-local-file:///var/storage/secattach/20251114/25619141.html

Protagenic Therapeutics completes Phase 1 dosing for PT00114 compound

Thu, 13 Nov 2025 08:22:11 +0000

Protagenic Therapeutics Inc. (NASDAQ: PTIX) announced it has completed enrollment and dosing in its Multiple Ascending Dose Phase 1 study for PT00114, its lead compound for stress-related neuropsychiatric and neurodegenerative disorders.

The study evaluated the safety and tolerability of PT00114 in healthy volunteers following multiple doses over time. All participants have now received their doses, marking a development milestone for the peptide-based therapeutic.

"We've completed all dosing for all healthy volunteers in the Phase 1 Study," said Dr. Garo Armen, Executive Chairman of Protagenic Therapeutics. "We plan to deliver a full summation of our analysis of the safety results within by the